Kosinski C, Zanchi A, Wojtusciszyn A. Diabète et infection à Covid-19. Rev Med Suisse 2020; 16:939-43.
Scheen AJ. Obésité et risque de Covid-19 sévère. Rev Med Suisse 2020; 16:1115-9.
Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and recent reports Diabetes Metab 2020; 46:265-71.
Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8:782-92.
Sun B, Huang SZhou J. Perspectives of antidiabetic drugs in diabetes with coronavirus infections. Front Pharmacol 2020; 11:592439.
Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: A nationwide observational study in England. Lancet Diabetes Endocrinol 2021; 9:293-303.
Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46:423-6.
Lalau JD, Al-Salameh A, Hadjadj S, et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab 2020; 47:101216.
Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab 2021; 47:101213.
Scheen AJ. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? Diabetes Metab 2020; 46:343-4.
Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus Nature Rev Endocrinol 2020; 16:556-77.
